Publication details

Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.

Authors

BLADÉ Joan SONNEVELD Pieter SAN MIGUEL Jesús F. SUTHERLAND Heather J. HÁJEK Roman NAGLER Arnon SPENCER Andrew ROBAK Tadeusz LANTZ Keith C. ZHUANG Sen H. HAROUSSEAU Jean-Luc ORLOWSKI Robert Z.

Year of publication 2011
Type Article in Periodical
Magazine / Source Clinical lymphoma, myeloma & leukemia
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.3816/CLML.2011.n.005
Field Oncology and hematology
Keywords Clinical outcomes; Multiple myeloma;Relapsed; refractory disease
Description Introduction: Bortezomib with pegylated liposomal doxorubicin (PLD) is superior to bortezomib alone in the relapsed and/or refractory setting, based on the results of a randomized, parallel-group, open-label, multicenter phase III study. To identify patients who might most benefit from this new standard of care, we performed retrospective analyses evaluating the effects of clinically defined, high-risk features on the outcomes with this regimen. Treatment of relapsed/refractory myeloma with the combination of PLD plus bortezomib provides better outcomes over bortezomib alone, even in the presence of high-risk prognostic factors. These results suggest that PLD plus bortezomib may represent an additional standard of care for this population of patients with multiple myeloma.

You are running an old browser version. We recommend updating your browser to its latest version.

More info